OCS — Oculis Holding AG stock price, charts and financials

NASDAQ·Healthcare·Biotechnology·Switzerland

Latest market price

11.99

+0.10+0.84%

Overview Short InterestFilings

OCSQT5Oculis Holding AG·NASDAQ

Overview Short InterestFilings

11.99+0.84%

Earnings

Up 0.8% — Earnings due 2026-08-06 — pre-report positioning.

Medium confidence

Loading chart...

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	57.17M	Perf Week	8.41%

Market Cap	685.46M	Forward P/E	-	EPS next Y	-2.11	Insider Trans	-	Shs Float	37.03M	Perf Month	-13.12%

Enterprise Value	411.46M	PEG	-	EPS next Q	-	Inst Own	35.94%	Short Float	4.06%	Perf Quarter	-57.57%

Income	-114.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	2.07	Perf Half Y	-58.70%

Sales	0.00	P/B	2.80	EPS next Y	2.89%	ROA	-39.08%	Short Interest	1.51M	Perf YTD	-39.96%

Book/sh	4.29	P/C	2.47	EPS next 5Y	-	ROE	-57.09%	52W High	34.48 -65.23%	Perf Year	-32.26%

Cash/sh	4.85	P/FCF	-	EPS past 3/5Y	-	ROIC	-42.07%	52W Low	10.52 13.97%	Perf 3Y	-2.08%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	-2889.37%	Volatility	4.84% 5.29%	Perf 5Y	24.64%

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	11.61%	Oper. Margin	-16740.95%	ATR (14)	0.74	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	5.18	Sales Y/Y TTM	-	Profit Margin	-18861.29%	RSI (14)	43.86	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	5.18	EPS Q/Q	18.18%	SMA20	-0.93%	Beta	0.22	Target Price	38.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-12.79%	Rel Volume	0.45	Prev Close	11.89

Employees	60	LT Debt/Eq	0.01	Earnings	Aug 06	SMA200	-45.29%	Avg Volume	688.07K	Price	11.99

IPO Date	May 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.13% -2.48%	Net Debt/EBITDA	0.66	Volume	310,990	Change	0.84%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-01-26	Reiterated	Robert W. Baird		$38
Jun-01-26	Reiterated	Needham	Buy	$38
Jun-01-26	Reiterated	HC Wainwright & Co.	Buy	$47 → $26
Jun-01-26	Reiterated	Guggenheim	Buy	$45
May-20-26	Initiated	Guggenheim	Buy
May-12-26	Reiterated	HC Wainwright & Co.	Buy	$36 → $47
Mar-04-26	Reiterated	Stifel Nicolaus		$40
Dec-19-25	Reiterated	Stifel Nicolaus		$40
Oct-08-25	Reiterated	Chardan Capital	Buy
Oct-07-25	Reiterated	HC Wainwright & Co.	Buy	$33 → $36

Latest News

Aug-03-26

Aug-03-2604:01AM

Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis DataBenzinga

04:00AM

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapsesglobenewswire.com

Jul-21-26

Jul-21-2602:20AM

OCS Group to buy Mitie for $4.17 billionreuters.com

Jul-17-26

Jul-17-2608:02AM

Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga

Jul-08-26

Jul-08-2604:05PM

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilitiesglobenewswire.com

Jul-02-26

Jul-02-2604:00AM

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conferenceglobenewswire.com

Company

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Ownership

Total institutional ownership35.94%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020
Total Revenue	0	1	0	0	0	0
Cost of Goods Sold Incl. D&A	0	59	0	0	0	0
Gross Profit	0	-58	0	0	0	0
Selling, General and Administrative Excl. Other	30	25	16	7	4	4
Research and Development	66	59	33	23	10	10
Other Operating Expense	-1	-59	41	4	0	-1
Operating Income	-95	-83	-90	-34	-14	-13
Interest Expense	1	1	2	7	6	3
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	-18	-14	-7	0	0	0
Net Income Before Taxes	-114	-98	-99	-40	-20	-16
Income Taxes	0	0	0	0	0	0
Consolidated Net Income	-114	-98	-99	-41	-20	-16
Net Income From Continuing Operations	-114	-98	-99	-41	-20	-16
Net Income	-114	-98	-99	-41	-20	-16
EPS (Recurring)	-2.18	-2.41	-3.31	-1.24	-0.62	-0.48
EPS (Basic, Before Extraordinaries)	-2.18	-2.41	-3.31	-1.24	-0.62	-0.48
EPS (Diluted)	-2.18	-2.41	-3.31	-1.24	-0.62	-0.48
EBITDA	-112	-97	-97	-33	-14	-13
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—
Price To Sales Ratio	—	680.00	—	—	—	—
Gross Margin	—	-5,800.00	—	—	—	—
Operating Margin	—	-8,300.00	—	—	—	—
Net Margin	—	-9,800.00	—	—	—	—
Shares Outstanding	52	40	30	33	33	33
Market Capitalization	1,038	680	337	333	320	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.